PharmTech Europe News

Pharmapack Report Points to Inhaled Pulmonary and Intranasal Drug Delivery as Areas to Watch

January 26, 2024

The annual industry report of the Pharmapack Europe event suggests there will be significant innovation in inhaled pulmonary and intranasal drug delivery in 2024.

EMA Looks Back at Medicines Approved in 2023

January 19, 2024

The agency recommended 77 drugs for marketing authorization in 2023, including 39 new APIs.

EMA Starts Safety Review of CAR T-Cell Medicines

January 17, 2024

The agency is reviewing data on secondary malignancies related to T-cells for approved CAR T-cell medicines.

Contract Packaging Set for High Growth in 2024

January 16, 2024

According to the Pharmapack Europe 2024 survey results, contract packaging will see growth over the coming 12 months.

AI Biotech Secures Funding to Speed Up Stem Cell Therapy Development

January 16, 2024

CellVoyant has raised £7.6 million in seed funding to speed up the development of novel cell therapies.

Precautionary Measures Recommended in Use of Valproate Medicines

January 15, 2024

The European Medicines Agency safety committee says there is a potential risk of neurodevelopment disorders in children born to men treated with valproate.

PharmaKure Gets Nod from MHRA to Trial Drug Targeting Amyloid Deposits

January 10, 2024

MHRA has granted a Clinical Trial Authorization to PharmaKure for its oral combined drug for the treatment of mild cognitive impairment.

Relative Bioavailability Trial of Nanotechnology-Enhanced Enzalutamide is Underway

January 10, 2024

Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide.

Bridging Gaps and Investing in Change

January 03, 2024

European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.

Frontrunners in Molecular Glues

January 03, 2024

Novel molecular glues are transforming targeted protein degradation.